Gastrointestinal Cancer News

November is Pancreatic Cancer Awareness Month, a campaign to draw attention to the disease, and raise funds for early diagnosis research and to raise awareness in various communities.

The FDA granted accelerated approval to larotrectinib for the treatment of adults and children with solid tumors that have a neurotrophic receptor tyrosine kinase gene fusion without a known acquired resistance mutation.

Stereotactic radiosurgery appeared comparable to surgical resection for controlling local brain metastases, according to an exploratory analysis of a randomized phase 3 trial.

Surveillance colonoscopies completed within the U.S. Multi-Society Task Force recommended 3-year interval following the removal of high-risk adenomas appear underutilized and vary by patient age and health care system location, according to results of a population-based study.

HPV vaccination rates among adolescents must increase substantially for the American Cancer Society to achieve its goal of 80% prevalence by 2026, according to study results published in Cancer.

A combination of dabrafenib and trametinib demonstrated promising efficacy in patients with rare gastrointestinal cancers linked to a mutation of the BRAF gene, according to research presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland.

Obesity during adolescence appeared associated with a fourfold increased risk for pancreatic cancer later in life, according to an analysis of 1.7 million Israeli Jewish men and women.

A randomized phase 3 trial designed to compare pembrolizumab with chemotherapy as second-line treatment of advanced or metastatic esophageal or esophagogastric junction carcinoma met its primary endpoint of OS among patients whose disease expressed PD-L1.

SAN FRANCISCO — Patients with advanced hepatocellular carcinoma with Child-Pugh B status experienced encouraging efficacy and safety outcomes after treatment with PD-1 inhibitor Opdivo, according to data presented at The Liver Meeting 2018.

SAN FRANCISCO — Individuals with hepatitis C who underwent DAA therapy experienced significant reductions in both hepatocellular carcinoma and decompensation risk compared with untreated patients, according to data presented at The Liver Meeting 2018.